Representing 58.4% of Total RevenueStrong Q3 Profitability: 9.0% Net Income margin and 32.8% Adjusted EBITDA marginUpdates ...

The table below comprises the names of units which are part of the latest syllabus for the 2025 exams. These chapters are intact with minor additions. Discovery of Electron, Proton, and Neutron, ...

From the November/December 2025 issue of Car and Driver.

Robust balance sheet with access to over A$86.3M in funding comprising of, A$17.5M in cash, US$43.4M (A$65.5M) 24 month award ...

Châtillon, France, October 28, 2025DBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a ...

Revenue of $13.6 million Backlog of $21.1 million as of September 30, 2025 Reaffirms expectation for 2025 revenue between $50 and $60 million Reaffirms ...

Q4 2025 Earnings Call October 27, 2025 4:30 PM EDTCompany ParticipantsSuzanne DuLong - Vice President of Investor ...

Good afternoon. Welcome to the Amprius Technologies Third Quarter 2025 Earnings Conference Call. Joining us for today's presentation are the company's CEO, Dr. Kang Sun; President, Tom Stepien; and ...

Châtillon, France, October 28, 2025 DBV Technologies Reports Third Quarter 2025 Financial Results DBV closes Q3 2025 with a cash and cash equivalents balance of $69.8 million, taking cash runway ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the third quarter ended September 30, 2025. “Amneal delivered another strong quarter and updated ...